2024 (3 POSTS)
Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K , et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680 . PMID: 38991779.
View Abstract
Publication: Manuscripts
Mihalchik AL , Choksi NY , Roe AL, Wisser M, Whitaker K, Seibert D, Deore M, Pavlick L, Wikoff DS . 2024. Safety evaluation of 8 drug degradants present in over-the-counter cough and cold medications. Regul Toxicol Pharmacol 149(May):105621; doi: 10.1016/j.yrtph.2024.105621 . PMID: 38608922.
View Abstract
Publication: Manuscripts
Burnett J, Sychterz C, Zhu D, Shakeel F, Dingley K , Chen W, et al. Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug interaction (DDI) study: Case study of mezigdomide. Poster presented at American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Colorado Springs, CO, March 2024.
View Abstract
Publication: Abstracts and Presentations
2022 (1 POST)
Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K , Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.
View Abstract
Publication: Abstracts and Presentations
2021 (1 POST)
Robison TW . How many doses of an Ames-positive/mutagenic (DNA reactive) drug can be safely administered to healthy subjects? Genetic Toxicology Association, 2021.
Publication: Abstracts and Presentations
2020 (1 POST)
Elbeddini A, Hooda N , Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058 . PMID: 32594093.
View Abstract
Publication: Manuscripts
2014 (1 POST)
Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K , Olson S, Taub ME, et al. 2014. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in HCV patients. J Pharmacol Exp Ther 351(2):403–412; doi: 10.1124/jpet.114.218081 . PMID: 25204339.
View Abstract
Publication: Manuscripts
2013 (1 POST)
Robison TW . Regulatory review of XELJANZ® (Tofacitinib) from the nonclinical perspective. American College of Toxicology Annual Meeting, 2013.
Publication: Abstracts and Presentations
2012 (1 POST)
Mease K , Sane RS, Podila L, Taub ME. 2012. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP and MRP2. J Pharm Sci 101(5):1888–1897; doi: 10.1002/jps.23069 . PMID: 22359351.
View Abstract
Publication: Manuscripts
2011 (1 POST)
Taub ME, Mease K , Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, et al. 2011. Digoxin is not a substrate for organic anion transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium dependent transporter expressed in HEK293 cells. Drug Metab Disp 39(11):2093–2102; doi: 10.1124/dmd.111.040816 . PMID: 21849517.
View Abstract
Publication: Manuscripts
2007 (1 POST)
Urban JD , Vargas G, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacol 32(1):67-77; doi: 10.1038/sj.npp.1301071 .
View Abstract
Publication: Manuscripts
2004 (1 POST)
Urban JD , Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.
Publication: Abstracts and Presentations
1998 (1 POST)
Thompson CM , Kawashima H, and Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 359(1):115–121; doi: 10.1006/abbi.1998.0892 .
View Abstract
Publication: Manuscripts
1994 (1 POST)
Choksi NY , Hussain A, Owens CE, Myers AM, Harvey RD, Baldessarini RJ, Wyrick SD, Booth RG. Adenosine A2 and PAT- σ3 agonists affect adenylyl cyclase activity and dopamine synthesis. Poster presented at North Carolina Society for Neuroscience Meeting, 1994.